Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

Share Price Information for Kanabo Grp Plc (KNB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.70
Bid: 1.50
Ask: 1.90
Change: 0.00 (0.00%)
Spread: 0.40 (26.667%)
Open: 1.70
High: 1.70
Low: 1.70
Prev. Close: 1.70
KNB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update: Amendments to Acquisition Agreement

16 May 2023 15:00

RNS Number : 6157Z
Kanabo Group PLC
16 May 2023
 

16 May 2023

Kanabo Group Plc

("Kanabo" or the "Company")

 

Update: Amendments to The GP Service Limited Acquisition Agreement

 

Further to announcement made earlier today, the Company would like to make the following clarifications.

 

· As announced on 21 February 2022, as part-consideration for the acquisition of The GP Service Limited, Kanabo was due to issue 12,574,931 new Ordinary Shares to MEIF WM Debt LP ("MEIF") on or around 22 August 2023, at an issue price of 12.65p per share.

· Following the successful completion of the £2.74 million fundraise by the Company earlier this month, and with the consent of MEIF, the Company believes that it was beneficial for all stakeholders that the issuance date of these consideration shares should be extended to 31 December 2024.

· All other terms of the original February 2022 agreement, aside from this extension date, remain the same, including the number of shares to be issued, 12,574,931 and the issue price of 12.65p.

 

The Board of Kanabo gratefully acknowledges the de-facto commitment to the Company's long-term future being made by MEIF in consenting to this extension and considers that this removes any form of short-term share 'overhang' that the market may have believed existed with the original proposed August 2023 issuance date.

 

Alongside the successful closing of the recent fundraising and the appointment of Ian Mattioli as Non-Executive Chair, this is a further positive development which shows the strong belief stakeholders of the Company have in the future of Kanabo Group Plc.

 

 

For further information, please contact:

 

Kanabo Group Plc

via Vigo Consulting

Avihu Tamir, Chief Executive Officer

+44 (0)20 7390 0230

Assaf Vardimon, Chief Financial Officer

Ian Mattioli, Non-Executive Chair of the Board

 

Peterhouse Capital Ltd (Financial Adviser and Broker)

Eran Zucker/ Lucy Williams / Charles Goodfellow

 

+44 (0)20 7469 0930

Vigo Consulting (Financial Public Relations/Investor Relations)

Jeremy Garcia / Fiona Hetherington / Verity Snow

kanabo@vigoconsulting.com

 

 

 

 +44 (0)20 7390 0230

 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

 

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

 

Visit www.kanabogroup.com for more information.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEADSKFSSDEFA
Date   Source Headline
28th Mar 20247:00 amRNSExpansion of Treat It to Mental Health Treatments
27th Mar 20245:11 pmRNSHolding(s) in Company
25th Mar 20247:00 amRNSGermany Medical Cannabis Legislation Reform
18th Mar 20249:14 amRNSAgritec Update
15th Jan 20247:00 amRNSPartnership to launch a Walk-In Pain Clinic
14th Nov 20237:00 amRNSContract Extension With Major UK Retailer
2nd Nov 20237:00 amRNSPartnership with BRITISH CANNABISâ„¢
29th Sep 20237:00 amRNSHalf-Year Results
31st Aug 202311:13 amRNSTotal Voting Rights
11th Aug 202311:36 amRNSIssuance of New Ordinary Shares and TVR
26th Jul 20232:00 pmRNSAdmission and Total Voting Rights
24th Jul 20234:10 pmRNSIssuance of New Ordinary Shares and TVR
17th Jul 20237:00 amRNSSuccess for Kanabo Agritec with Contract Award
10th Jul 202311:19 amRNSIssue of New Ordinary Shares and TVR
30th Jun 20232:34 pmRNSResult of AGM
28th Jun 20237:00 amRNSIssue of New Ordinary Shares and TVR
23rd Jun 20237:00 amRNSGrant of Options
13th Jun 20232:39 pmRNSPublication of a Prospectus
8th Jun 20235:19 pmRNSNotice of Annual General Meeting
31st May 202311:30 amRNSTotal Voting Rights
26th May 202310:30 amRNSTotal Voting Rights
23rd May 202311:00 amRNSIssuance of New Ordinary Shares
16th May 20233:00 pmRNSUpdate: Amendments to Acquisition Agreement
16th May 20237:00 amRNSAmendments to Acquisition Agreement
15th May 20237:00 amRNSTotal Voting Rights
12th May 20237:00 amRNSTotal Voting Rights
10th May 20232:52 pmRNSResult of Broker Option
9th May 20237:00 amRNSAppointment of Ian Mattioli as Non-Executive Chair
9th May 20237:00 amRNSFundraise of £2.54 million and Broker Option
4th May 20234:45 pmRNSBoard Change
2nd May 20237:00 amRNSFull Year Results 2022
31st Mar 20232:40 pmRNSDirectorate Change
13th Mar 20237:00 amRNSTreat It Launch: Online Medicinal Cannabis Clinic
7th Mar 202312:15 pmRNSAppointment of Auditor
14th Feb 20234:40 pmRNSSecond Price Monitoring Extn
14th Feb 20234:35 pmRNSPrice Monitoring Extension
14th Feb 20237:00 amRNSBusiness Update
2nd Feb 20239:05 amRNSSecond Price Monitoring Extn
2nd Feb 20239:00 amRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
25th Jan 20232:05 pmRNSSecond Price Monitoring Extn
25th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 202311:05 amRNSSecond Price Monitoring Extn
25th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSLaunch of new products
30th Dec 20227:00 amRNSBoard Changes
2nd Dec 20222:59 pmRNSResignation of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.